Showing results (21-30 of 800) with videos related to
Sort By:
Pageof 80
Leukemia & Lymphoma|July 16, 2005
The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapyHagop M Kantarjian, Carlos E Bueso-Ramos, Moshe Talpaz, et al.Cancer|January 26, 2006
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndromeHagop Kantarjian, Miloslav Beran, Jorge Cortes, et al.Cancer|July 9, 2004
Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemiaCarlos E Bueso-Ramos, Jorge Cortes, Moshe Talpaz, et al.Haematologica|February 14, 2007
Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemiaWanlong Ma, Richard Tseng, Mercedes Gorre, et al.Cancer|December 13, 2005
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapyGautam Borthakur, Hagop Kantarjian, George Daley, et al.American Journal of Hematology|October 21, 2004
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experienceBryan Hennessy, Francis Giles, Jorge Cortes, et al.Current Opinion in Hematology|February 4, 2006
Overcoming drug resistance in chronic myeloid leukemiaJorge CortesHematology/Oncology Clinics of North America|July 24, 2004
Natural history and staging of chronic myelogenous leukemiaJorge CortesCurrent Hematology Reports|August 7, 2003
CMML: a biologically distinct myeloproliferative diseaseJorge CortesPageof 80